BioSpace News Archive

Nanoscope Therapeutics Inc., a clinical-stage biotechnology company developing gene therapies for retinal degenerative diseases, today announced that two executive team members will participate and present at the World Orphan Drug Congress, taking place July 11-13, at Hynes Center in Boston.

KAHR , a clinical-stage cancer immunotherapy company developing novel bi-functional fusion proteins, today announced the appointment of Jennifer Minai-Azary to its Board of Directors. The appointment is effective immediately.

Zynex, Inc . (NASDAQ: ZYXI), an innovative medical technology company specializing in the manufacture and sale of non-invasive medical devices for pain management, rehabilitation, and patient monitoring, today announced preliminary results for second quarter 2022 and reiterated full year guidance.

Biomica Ltd. today announced the successful enrollment of the first patient in its first Proof-of-Concept (POC) Phase I clinical trial.

MediPharm Labs Corp. (TSX: LABS) (OTCQX: MEDIF) (FSE: MLZ) (“MediPharm Labs” or the “Company”) has entered into a Share Purchase Agreement (the “Agreement”) with OneLife Botanicals PTY (“OneLife Botanicals”) for the sale of MediPharm Labs Australia Pty Ltd (“MPLA”), a wholly-owned subsidiary of the Company, for a minimum value of $6.9M AUD ($6.2M CAD).

Ionis Pharmaceuticals, Inc. (Nasdaq: IONS), today announced that its long-standing partner, Roche, will license and advance IONIS-FB-L Rx.

LOTIS-5 is intended to serve as the basis for a supplemental BLA (sBLA) in the U.S. and China in second-line transplant ineligible DLBCL.

Oral presentation evaluating feasibility of BgRT using long-lived immune PET tracer awarded Best in Physics.

Further analysis of Phase III COMFORT ™ data show Piclidenoson’s superior safety profile and higher patient compliance compared to Otezla ®.

New and recent director nominees include industry trailblazers BJ Jones of Biohaven Pharmaceuticals; Christine Lemke of Evidation Health; Ken Ehlert, formerly of UnitedHealth Group; and Chamath Palihapitiya of Social Capital and SCS.